What were the key takeaways from ANI Pharmaceuticals's earnings call?

What were the key takeaways from ANI Pharmaceuticals’s earnings call?

What does ANI Pharmaceuticals do and what are its main business segments?

What is the revenue and EPS growth rate for ANI Pharmaceuticals year over year?

What is ANI Pharmaceuticals's gross profit margin?

What is ANI Pharmaceuticals's latest dividend and current dividend yield?

Did ANI Pharmaceuticals beat or miss consensus estimates last quarter?

What factors drove the changes in ANI Pharmaceuticals's revenue and profit?

- **Record Growth**: Q3 2025 revenue up 54% YoY, driven by 93.8% surge in Cortrophin Gel to $101.9M.
- **Guidance Raise**: 2025 net revenue target $854-873M (+39-42%), Cortrophin Gel forecast $347-352M (+75-78%).
- **Generics Momentum**: Low 20% growth for 2025, though Q4 may dip due to competitive pressure.
- **ILUVIEN Reset**: 2026 focus on Medicare access and new label adoption, with 10x addressable patient potential.
- **Financial Strength**: $262.6M cash, 1.7x net leverage, and 59.2% adjusted EBITDA margin.

**【CEO Summary Section】**
- **Q3 2025 Performance**: Total revenue grew 54% YoY ($227.8M), with 46% organic growth. Adjusted EBITDA increased 70% to $59.6M. Cortrophin Gel net revenue reached $101.9M, up 93.8% YoY, driven by new patient starts and expanded sales force.
- **2025 Guidance Update**: Full-year net revenue expected to rise 39-42% to $854-873M. Cortrophin Gel forecasted at $347-352M (75-78% growth). Generics growth in low 20% range, though Q4 may dip due to competitive entrants.
- **Strategic Focus**: Rare Disease remains top priority. ILUVIEN faces Medicare access challenges but shows potential for 2026 growth with new label adoption and specialty pharmacy pathways.

**【CFO Financial Commentary】**
- **Q3 Financials**: GAAP net revenue $227.8M (53.6% YoY). Rare Disease segment contributed $118.5M, with Generics at $94.4M. Adjusted EBITDA margin 59.2%, down 63bps due to partnered generic product mix.
- **Cash Flow & Balance Sheet**: $262.6M in unrestricted cash. Full-year 2025 EBITDA guidance raised to $221-228M. Gross leverage 3x, net leverage 1.7x trailing EBITDA.
- **Generics Outlook**: Low 20% growth for 2025, but Q4 expected to decline due to competitive pressure on a key partnered product.

**【Q&A Highlights】**
- **Cortrophin Growth Drivers**: 42% sequential increase in ophthalmology volume. Prefilled syringe adoption at 70% of new cases. Addressable patient populations (e.g., acute gouty arthritis: 285K) underpenetrated, with half of prescribers new to ACTH.
- **Generics Challenges**: Q4 dip in Generics due to competitive entrants, but long-term pipeline remains strong.
- **ILUVIEN Strategy**: 2026 focus on peer-to-peer education, Medicare Part D access via specialty pharmacy, and NEW DAY study dissemination.
- **Sales Force Expansion**: ROI validated by record new patient starts. Pulmonology and neurology show growth potential.
- **Durability of Cortrophin**: Patents extend to 2040s; porcine-derived formulation poses high generic entry barriers.

ANIP

ANIP fundamentals

You can ask Aime